Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: Fenofibrate, used in the treatment of hypercholesterolemia or mixed dyslipidemia, increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 15/December/2016, 10.22 pm

Small molecule-based PD-1 pathway blockade for Human cancer therapy: NCYM, a Cis-Antisense Gene of MYCN, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 14/December/2016, 11.01 pm
December 14, 2016
Anti-telomerase cancer therapy: MiR-30b suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene, 15/December/2016, 10.37 pm
December 15, 2016
Show all

From Significance of the study to Public health relevance:

Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From therapeutic strategy to Research Findings:

(i) Therapeutic strategy: 

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.

(ii) Research findings:  

Fenofibrate, by increasing the expression of its target genes, it may not only increase the expression of tumor suppressors genes, such as TAp73, TAp63, PTEN, etc., but also increase a number of metastatic suppressor genes, such as TPM1, TIMP3, BTG2, PDCD4, SPRY1/2, CCM1/KRIT1 etc. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53 (figure1).

fenofibrate-induces-the-expression-of-tap63-p73-to-regress-mutant-p53-exp-tumors

Figure 1. Fenofibrate functions as an anticancer drug by activating tumor suppressor genes, such as TAp73, TAp63, PTEN, PDCD4, BTG2, etc., and metastatic suppressor genes, such as TPM1, TIMP3, SPRY1/2 etc., in human metastatic mutant-p53 expressing tumors


Therapeutic opportunity:

Given the ability of Fenofibrate to induce the expression of TAp73, TAp63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2, CCM1/KRIT1, long ncRNA Gas5 in p53-mutated human tumors, pharmacological formulations encompassing Fenofibrate or its analogues or Fenofibrate plus any of the known anticancer agents” may be used to inhibit the progression of p53-mutated invasive metastatic tumors.

price-100

Together, this study suggests a natural-product-based therapy for p53-mutated metastatic human tumors.[easy_payment currency=”USD”]


Details of the research findings

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100#

Undisclosed mechanistic information: How Fenofibrate increases the expression of tumor suppressor genes (TAp73, TAp63, and PTEN); and  metastatic suppressor genes (TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1) in mutant p53 expressing cancer cells?

For purchase and payment details, you may reach us at admin@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors:   Fenofibrate, used in the treatment of hypercholesterolemia or mixed dyslipidemia, increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 15/December/2016, 10.21 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.